Articles NICE calls the shots on Harvoni – but NHS England eyeing pri... Harvoni and rival hep C drugs look set for approval in England – but NHS England may have the last word on controlling costs, finds Andrew McConaghie.
Articles Market access for specialist medicines in the UK: the Price ... A recent pharmaphorum webinar brought four experts together to discuss the future of market access for specialist medicines in the UK.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.